In the present study, we aimed to detect the levels of CXCL1, CXCL5, and CXCL7 in the CSF of patients with NMO and compared with patients with MS and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. This evidence concerns the gene CXCL5 and myeloid sarcoma.